BioWorld

Feb. 26, 2004

View Archived Issues

Stressgen Reports Mixed HspE7 Data, Moves Drug Forward In RRP

Recurrent respiratory papillomatosis represents the first indication that Stressgen Biotechnologies Corp. intends to pursue with its drug HspE7, based on positive Phase II data released this week. (BioWorld Today) Read More

Sector 'Buoyant' Despite Unclear Future, Says Outgoing BIO Chief

Read More

Drug Makers Have Two Years To Put Bar Codes On Products

Read More

Pivotal Study Of Dynavax's Ragweed Drug Under Way

Read More

Other News To Note

Read More